Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Adjuvant Treatment of High-Risk Endometrial Cancer
NCT04634877Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2021
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 28
01
Overview
A Phase 3 trial of pembrolizumab in endometrial cancer (EC), sponsored by Merck & Co.. Started Jan 2021; status: active, not recruiting.
02
Drugs
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04634877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04634877.